Laboratory measurements of the oral direct factor Xa inhibitor edoxaban: Comparison of prothrombin time, activated partial thromboplastin time, and thrombin generation assay

American Journal of Clinical Pathology

Volumn 143, Issue 2, 2015, Pages 241-247

  Morishima, Yoshiyuki ^a   Kamisato, Chikako ^a  

^a Biological Research Laboratories   (Japan)

Author keywords

Activated partial thromboplastin time; Coagulation assay; Direct factor Xa inhibitor; Monitoring; Prothrombin time; Thrombin generation assay

Indexed keywords

EDOXABAN; BLOOD CLOTTING FACTOR 10A INHIBITOR; PYRIDINE DERIVATIVE; THIAZOLE DERIVATIVE; THROMBIN;

ABSORPTION LAG TIME; ANTICOAGULANT THERAPY; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG EFFECT; HUMAN; IC50; PARTIAL THROMBOPLASTIN TIME; PRIORITY JOURNAL; PROTHROMBIN TIME; THROMBOCYTE POOR PLASMA; THROMBOCYTE RICH PLASMA; BLOOD CLOTTING; BLOOD CLOTTING TEST; COMPARATIVE STUDY; DRUG EFFECTS; PROCEDURES;

BLOOD COAGULATION; BLOOD COAGULATION TESTS; FACTOR XA INHIBITORS; HUMANS; PARTIAL THROMBOPLASTIN TIME; PLATELET-RICH PLASMA; PROTHROMBIN TIME; PYRIDINES; THIAZOLES; THROMBIN;

EID: 84925284867     PISSN: 00029173     EISSN: 19437722     Source Type: Journal    
DOI: 10.1309/AJCPQ2NJD3PXFTUG     Document Type: Article

References (25)

1. Yeh CH, Fredenburgh JC, Weitz JI. Oral direct factor Xa inhibitors. Circ Res. 2012;111:1069-1078.
2. Ruff CT, Giugliano RP, Braunwald E, et al. Comparison of the efficacy and safety of new oral anticoagulants with warfarin in patients with atrial fibrillation: a meta-analysis of randomised trials. Lancet. 2014;383:955-962.
3. Van Der Hulle T, Kooiman J, Den Exter PL, et al. Effectiveness and safety of novel oral anticoagulants compared with vitamin K-antagonists in the treatment of acute symptomatic venous thromboembolism: a systematic review and metaanalysis. J Thromb Haemost. 2014;12:320-328.
4. Hankey GJ. Unanswered questions and research priorities to optimise stroke prevention in atrial fibrillation with the new oral anticoagulants. Thromb Haemost. 2014;111:808-816.
5. Ten Cate H. New oral anticoagulants: discussion on monitoring and adherence should start now! Thromb J. 2013;11:8.
6. Furugohri T, Isobe K, Honda Y, et al. DU-176b, a potent and orally active factor Xa inhibitor: in vitro and in vivo pharmacological profiles. J Thromb Haemost. 2008;6:1542-1549.
7. Ogata K, Mendell-Harary J, Tachibana M, et al. Clinical safety, tolerability, pharmacokinetics, and pharmacodynamics of the novel factor Xa inhibitor edoxaban in healthy volunteers. J Clin Pharmacol. 2010;50:743-753.
8. Fujita S, Fuji T, Tachibana S, et al. Safety and efficacy of edoxaban in patients undergoing hip fracture surgery. Pathophysiol Haemost Thromb. 2010;37:A95, P366.
9. Fuji T, Fujita S, Tachibana S, et al. Efficacy and safety of edoxaban versus enoxaparin for the prevention of venous thromboembolism following total hip arthroplasty: STARS J-V trial. ASH Annual Meeting Abstracts. 2010;116:3320.
10. Fuji T, Fujita S, Tachibana S, et al. Edoxaban versus enoxaparin for the prevention of venous thromboembolism: pooled analysis of venous thromboembolism and bleeding from STARS E-3 and STARS J-V. ASH Annual Meeting Abstracts. 2011;118:208.
11. Giugliano RP, Ruff CT, Braunwald E, et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med. 2013;369:2093-2104.
12. Hokusai-VTE Investigators, Büller HR, Décousus H, et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med. 2013;369:1406-1415.
13. Weitz JI, Connolly SJ, Patel I, et al. Randomised, parallelgroup, multicentre, multinational phase 2 study comparing edoxaban, an oral factor Xa inhibitor, with warfarin for stroke prevention in patients with atrial fibrillation. Thromb Haemost. 2010;104:633-641.
14. Hirsh J. Optimal intensity and monitoring warfarin. Am J Cardiol. 1995;75:39B-42B.
15. Hemker HC, Giesen P, AlDieri R, et al. The calibrated automated thrombogram (CAT): a universal routine test for hyper- and hypocoagulability. Pathophysiol Haemost Thromb. 2002;32:249-253.
16. Gerotziafas GT, Petropoulou AD, Verdy E, et al. Effect of the anti-factor Xa and anti-factor IIa activities of low-molecularweight heparins upon the phases of thrombin generation. J Thromb Haemost. 2007;5:955-962.
17. Samama MM, Le Flem L, Guinet C, et al. Three different patterns of calibrated automated thrombogram obtained with six different anticoagulants. J Thromb Haemost. 2007;5:2554-2556.
18. Samama MM, Mendell J, Guinet C, et al. In vitro study of the anticoagulant effects of edoxaban and its effect on thrombin generation in comparison to fondaparinux. Thromb Res. 2012;129:e77-e82.
19. Samama MM, Martinoli JL, LeFlem L, et al. Assessment of laboratory assays to measure rivaroxaban-an oral, direct factor Xa inhibitor. Thromb Haemost. 2010;103:815-825.
20. Barrett YC, Wang Z, Frost C, et al. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost. 2010;104:1263-1271.
21. Samama MM, Kunitada S, Oursin A, et al. Comparison of a direct factor Xa inhibitor, edoxaban, with dalteparin and ximelagatran: a randomised controlled trial in healthy elderly adults. Thromb Res. 2010;126:e286-e293.
22. Barrett YC, Wang Z, Frost C, et al. Clinical laboratory measurement of direct factor Xa inhibitors: anti-Xa assay is preferable to prothrombin time assay. Thromb Haemost. 2010;104:1263-1271.
23. Samama MM, Contant G, Spiro TE, et al. Evaluation of the anti-factor Xa chromogenic assay for the measurement of rivaroxaban plasma concentrations using calibrators and controls. Thromb Haemost. 2012;107:379-387.
24. Gouin-Thibault I, Flaujac C, Delavenne X, et al. Assessment of apixaban plasma levels by laboratory tests: suitability of three anti-Xa assays. A multicentre French GEHT study. Thromb Haemost. 2014;111:240-248.
25. Francart SJ, Hawes EM, Deal AM, et al. Performance of coagulation tests in patients on therapeutic doses of rivaroxaban: a cross-sectional pharmacodynamic study based on peak and trough plasma levels. Thromb Haemost. 2014;111:1133-1140.